bortezomib [clinicaltrials_resource:30918a22e12afee8cb035d4ed1dbe4b7]
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome [clinicaltrials:NCT00005064]Bortezomib in Treating Patients With Recurrent Glioma [clinicaltrials:NCT00006773]Bortezomib in Treating Children With Advanced Solid Tumors [clinicaltrials:NCT00021216]clinicaltrials:NCT00023712PS-341 in Treating Patients With Metastatic Malignant Melanoma [clinicaltrials:NCT00024011]PS-341 in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00025584]Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer [clinicaltrials:NCT00040768]Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction [clinicaltrials:NCT00054483]Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma [clinicaltrials:NCT00072150]clinicaltrials:NCT00075881Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) [clinicaltrials:NCT00077441]
intervention [clinicaltrials_vocabulary:intervention]
bortezomib [clinicaltrials_resource:30918a22e12afee8cb035d4ed1dbe4b7]
Bio2RDF identifier
30918a22e12afee8cb035d4ed1dbe4b7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:30918a22e12afee8cb035d4ed1dbe4b7
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
intervention name [clinicaltrials_vocabulary:intervention-name]
bortezomib
other name [clinicaltrials_vocabulary:other-name]
identifier
clinicaltrials_resource:30918a22e12afee8cb035d4ed1dbe4b7
title
bortezomib
@en
type
label
bortezomib [clinicaltrials_resource:30918a22e12afee8cb035d4ed1dbe4b7]
@en